Edition:
United Kingdom

Evotec SE (EVTG.DE)

EVTG.DE on Xetra

21.85EUR
4:35pm BST
Change (% chg)

€-0.22 (-1.00%)
Prev Close
€22.07
Open
€22.31
Day's High
€22.40
Day's Low
€21.79
Volume
787,903
Avg. Vol
981,890
52-wk High
€25.83
52-wk Low
€12.06

Latest Key Developments (Source: Significant Developments)

Evotec Pays Back 140 Mln Euro Bridge Loan
Thursday, 18 Apr 2019 

April 18 (Reuters) - Evotec SE ::DGAP-NEWS: EVOTEC COMPLETES REPAYMENT OF EUR 140 M ACQUISITION LOAN.EVOTEC COMPLETES REPAYMENT OF EUR 140 M ACQUISITION LOAN.BRIDGE LOAN WAS DRAWN TO SECURE EVOTEC'S VALUE CHAIN EXPANSION BY SUCCESSFUL ACQUISITION OF APTUIT IN AUGUST 2017.  Full Article

Evotec And Indivumed Announce Strategic Drug Discovery Collaboration
Thursday, 11 Apr 2019 

April 11 (Reuters) - Evotec SE ::DGAP-NEWS: EVOTEC AND INDIVUMED ANNOUNCE STRATEGIC DRUG DISCOVERY COLLABORATION ON PRECISION MEDICINE FOR COLORECTAL CANCER.DGAP-NEWS: EVOTEC AND INDIVUMED ANNOUNCE STRATEGIC DRUG DISCOVERY COLLABORATION ON PRECISION MEDICINE FOR COLORECTAL CANCER.COLLABORATION RUNS FOR AN INITIAL TERM OF TWO YEARS.GOAL OF COLLABORATION IS TO DELIVER HIGHLY EFFECTIVE AND DURABLE TREATMENTS WITH CLEAR STRATEGIES FOR CRC PATIENT STRATIFICATION.  Full Article

Evotec Sees Adjusted EBITDA Up 10 Pct In 2019
Thursday, 28 Mar 2019 

March 28 (Reuters) - Evotec AG ::DGAP-NEWS: EVOTEC AG FISCAL YEAR 2018 RESULTS: ACCELERATED GROWTH AND STRONG LONG-TERM OUTLOOK.42% INCREASE IN GROUP REVENUES, ADJUSTED GROUP EBITDA UP 67%.STRONG START AND OUTLOOK FOR FISCAL YEAR 2019.GROUP REVENUES UP 42% TO EUR 375.4 M.ADJUSTED GROUP EBITDA UP 67% TO EUR 95.5 M (2017: EUR 57.2 M).STRONG STRATEGIC LIQUIDITY POSITION OF EUR 149.4 M.GROUP REVENUES EXPECTED TO INCREASE BY APPROX. 10%.ADJUSTED GROUP EBITDA EXPECTED TO IMPROVE BY APPROX. 10%.WILL FOCUS ITS GUIDANCE AND REPORTING DURING COURSE OF 2019 ON "UNPARTNERED RESEARCH AND DEVELOPMENT" PART, ESTIMATED AT APPROX. EUR 30-40 M.CURRENTLY, EVOTEC DOES NOT PLAN AN DISTRIBUTION OF DIVIDENDS.  Full Article

Evotec: New Partnership With GARDP To Discover Antibiotics
Tuesday, 19 Mar 2019 

March 19 (Reuters) - Evotec AG ::EVOTEC AND GARDP ANNOUNCE NEW PARTNERSHIP TO DISCOVER NOVEL ANTIBIOTICS.DISCOVERY EFFORTS WILL FOCUS ON WORLD HEALTH ORGANIZATION ("WHO") PRIORITY PATHOGENS.BY JOINING FORCES, EVOTEC AND GARDP WILL LEVERAGE THEIR CAPABILITIES AND NETWORKS TO ADDRESS DRUG-RESISTANT BACTERIAL INFECTIONS.  Full Article

Evotec Receives Payment For Chronic Cough Medicine Second Phase Trial
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Evotec AG ::DGAP-NEWS: EVOTEC RECEIVES MILESTONE PAYMENT FOR START OF SECOND PHASE II TRIAL IN ITS MULTI-TARGET ALLIANCE WITH BAYER.SMALL MOLECULE FROM ITS MULTI-TARGET ALLIANCE WITH BAYER HAS ADVANCED INTO PHASE II CLINICAL DEVELOPMENT FOR TREATMENT OF PERSISTENT CHRONIC COUGH.AS A RESULT OF TRIAL INITIATION, EVOTEC RECEIVED A PAYMENT OF EUR 3 M.  Full Article

Evotec Invests In Financing Round Of Exscientia
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Evotec AG ::EVOTEC INVESTS IN FINANCING ROUND OF EXSCIENTIA.PROCEEDS TO ACCELERATE SCALING AS LEADING AI DRUG DISCOVERY COMPANY.$ 26 M FINANCING ROUND (SERIES B) INCLUDES CELGENE, GT HEALTHCARE CAPITAL PARTNERS AND EVOTEC.  Full Article

Evotec Increases Its EBITDA Guidance For 2018
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - Evotec AG ::DGAP-ADHOC: EVOTEC AG INCREASES ITS PROFITABILITY GUIDANCE FOR 2018.NOW EXPECTS FY ADJUSTED GROUP EBITDA* TO INCREASE BY MORE THAN 45%.ALL OTHER ELEMENTS OF COMPANY'S FINANCIAL GUIDANCE ARE CONFIRMED..SHARES UP 7.2 PERCENT AFTER INCREASES EBITDA FORECAST.  Full Article

Evotec And Leo Pharma Form Skin Drug Discovery Alliance
Tuesday, 4 Dec 2018 

Dec 4 (Reuters) - Evotec AG ::DGAP-NEWS: EVOTEC AND LEO PHARMA FORM DRUG DISCOVERY ALLIANCE TARGETING DERMATOLOGICAL CONDITIONS.COLLABORATION GOAL IS TO GENERATE NEW LEADS AGAINST INNOVATIVE TARGETS FOR A RANGE OF DERMATOLOGICAL CONDITIONS AND INITIALLY RUNS FOR TWO YEARS.EVOTEC'S INTEGRATED DISCOVERY SCIENTISTS WILL WORK IN A JOINT TEAM WITH SCIENTISTS FROM LEO PHARMA.ALLIANCE WILL RECEIVE FURTHER SUPPORT WITH HIGH-VALUE DRUG DEVELOPMENT AND DISCOVERY ADME-TOX SERVICES.NO FINANCIAL DETAILS OF THIS FEE-FOR-SERVICE COLLABORATION WERE DISCLOSED.  Full Article

Evotec confirms 2018 outlook, appoints Craig Johnstone COO
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Evotec AG ::9M REVENUE ROSE 57 PERCENT TO 270 MILLION EUR.57% INCREASE IN GROUP REVENUES, 77% INCREASE IN ADJUSTED GROUP EBITDA.STRONG OUTLOOK FOR 2018 CONFIRMED AND GOOD UNDERLYING BUSINESS INDICATIONS FOR 2019.GROUP REVENUES: 57% INCREASE TO EUR 270.0 M (9M 2017: EUR 171.5 M).EVT EXECUTE REVENUES UP 53% TO EUR 254.3 M (9M 2017: EUR 165.8 M);.EVT INNOVATE REVENUES UP 55% TO EUR 51.3 M (9M 2017: EUR 33.2 M).ADJUSTED GROUP EBITDA UP 77% TO EUR 68.7 M (9M 2017: EUR 38.9 M).ADJUSTED EBITDA FOR EVT EXECUTE OF EUR 62.1 M (9M 2017: EUR 41.4 M).ADJUSTED EBITDA FOR EVT INNOVATE OF EUR 6.6 M (9M 2017: EUR (2.5) M).GROUP RESEARCH AND DEVELOPMENT EXPENSES INCREASE OF 67% TO EUR 20.9 M (9M 2017: EUR 12.5 M).STRONG LIQUIDITY POSITION OF EUR 168.6 M EVEN AFTER 50% (EUR 70 M).CLINICAL PHASE I AND PHASE II STARTS AND GOOD PROGRESS WITHIN ONGOING ALLIANCES (E.G. BAYER ENDOMETRIOSIS/CHRONIC COUGH ALLIANCE).SIGNING OF MULTIPLE NEW AND EXTENDED DRUG DISCOVERY AND DEVELOPMENT AGREEMENTS (E.G. CHDI, NOVO NORDISK, FERRING (AFTER PERIOD-END).NEW CONTRACTS AND INCREASED DEMAND FOR INDIGO SOLUTIONS AND DEVELOPMENT SERVICES (E.G. ANKAR, ASTEX, INFLAZOME, YUMANITY).STRONG PERFORMANCE ACROSS ALL BUSINESS AND SERVICE LINES (E.G. HIGH-THROUGHPUT ADME-TOX TESTING AT CYPROTEX, AN EVOTEC COMPANY).CHANGE IN MANAGEMENT BOARD AS OF 01 JANUARY 2019: APPOINTMENT OF DR CRAIG JOHNSTONE AS NEW COO; DR MARIO POLYWKA RETIRING FROM EVOTEC.GUIDANCE 2018 CONFIRMED.  Full Article

Evotec H1 Revenue Rises By 67 Pct
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Evotec AG ::H1 REVENUE ROSE 67 PERCENT TO 173.8 MILLION EUR.67% INCREASE IN GROUP REVENUES, 47% INCREASE IN ADJUSTED GROUP EBITDA.GROUP REVENUES: 67% INCREASE TO EUR 173.8 M (H1 2017: EUR 104.3 M).GUIDANCE ON GROUP REVENUES - GROWTH OF >30% CONFIRMED.GUIDANCE ON ADJUSTED GROUP EBITDA - GROWTH OF APPROX. 30% CONFIRMED.GUIDANCE ON RESEARCH AND DEVELOPMENT EXPENSES INCREASED - RESEARCH AND DEVELOPMENT EXPENSES FOR 2018 WILL INCREASE TO EUR 35-45 M.  Full Article

German stocks - Factors to watch on March 28

BERLIN/FRANKFURT, March 28 The following are some of the factors that may move German stocks on Thursday: